The weight-loss drug market has experienced incredible momentum over the past few years, and according to analyst projections, it hasn't peaked yet -- far from it. Among the many drugmakers looking to join this market is Altimmune (NASDAQ: ALT), a smaller biotech whose shares could skyrocket from their current levels if its leading program is successful. While the upside potential of a company like Altimmune is attractive, it's important to highlight that there is plenty of risk, too. A safer -- and argu ...

22% Collapse Looks Like A 'Buy The Dip' Moment[Austin Smith | Feb 9, 2026 at 11:59 AM EST Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled…]## What Losing CNN Means for Snap's Future[Jon C. Ogg | Dec 24, 2017 at 9:59 AM EST Snap has a serious issue about how it can and will grow its user base and engagement. And it has…]## Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly[Michael Williams | Jan 23, 2026 at 2:06 ...

Core Insights - Eli Lilly's Q4 earnings exceeded expectations with an EPS of $7.54 compared to the expected $6.67, and the company projected 2026 revenue between $80 billion and $83 billion [1] - The company's Mounjaro revenue increased by 110% to $7.4 billion in Q4, while Zepbound revenue rose by 123% to $4.2 billion [1] - Eli Lilly's operating margins reached 45.6% and net margins were at 31.7%, indicating strong financial performance [1] Financial Performance - Eli Lilly's stock was trading at $1,040, just 5.8% below its all-time high as of February 13, 2026 [1] - Retail sentiment shifted from neutral to bullish, with a sentiment score increase from 57.3 to 65.7 following the earnings report [1] - Analysts maintain a consensus target price of $1,201, with some projecting a higher target of $1,350 based on the company's growth potential [1] Strategic Initiatives - Eli Lilly has committed $1 billion to develop a supercomputer in collaboration with Nvidia to enhance drug discovery processes [1] - The establishment of a co-innovation lab with Nvidia aims to integrate clinical data with advanced computational capabilities [1] - The company has built a $1.5 billion stockpile of orforglipron, anticipating an FDA decision in April 2026, positioning itself for market capture [1] Competitive Landscape - Eli Lilly's GLP-1 franchise is outperforming competitors, with significant revenue growth compared to Novo Nordisk, which is facing projected sales declines of 5% to 13% in 2026 [1] - The company's quarterly revenue growth was reported at 42.6%, indicating strong momentum in its product pipeline [1]

Company Overview - Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing next-generation peptide-based therapeutics for metabolic and liver diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH) [4] - The lead candidate, pemvidutide, targets GLP-1 and glucagon receptors to reduce weight, liver fat, and cardiometabolic risk [4] Analyst Support and Market Outlook - Barclays initiated coverage of ALT with an Overweight rating and a $20 price target, citing strong underlying fundamentals and continuous merger and acquisition activity as reasons for optimism in the biotech industry by 2026 [2] - The firm also noted that ALT and other biotech stocks remain undervalued compared to their pipeline potential [2] Recent Developments - Altimmune announced plans to use net proceeds from a recent offering for working capital and preparation for its next Phase 3 MASH research [3] - The company received FDA's Breakthrough Therapy Designation and reported positive Phase 2b 48-week findings for pemvidutide, reinforcing its potential as a novel glucagon/GLP-1 dual agonist [3]

Core Viewpoint - U.S. stock futures are showing positive movement, particularly with Nasdaq 100 futures increasing by over 200 points, while Qorvo, Inc. has experienced a significant decline in pre-market trading following disappointing financial results and lower sales guidance for the upcoming quarter [1][2] Company Summary - Qorvo, Inc. expects its fiscal fourth-quarter revenue to be between $775 million and $825 million, which is below the market estimate of $904.59 million [2] - The company anticipates adjusted earnings per share for the fourth quarter to be in the range of $1.05 to $1.35, compared to the estimate of $1.37 per share [2] - In pre-market trading, Qorvo shares fell by 10.5%, reaching a price of $74.11 [2]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Murano Global Investments Plc (MRNO) is up 146% at $3.35 [3] - Kustom Entertainment, Inc. (KUST) is up 34% at $2.84 [3] - Ainos, Inc. (AIMD) is up 34% at $2.32 [3] - Stride, Inc. (LRN) is up 29% at $94.10 [3] - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is up 18% at $2.40 [3] - Battalion Oil Corporation (BATL) is up 16% at $3.83 [3] - C3.ai, Inc. (AI) is up 15% at $14.58 [3] - Lantronix, Inc. (LTRX) is up 14% at $7.87 [3] - Nextpower Inc. (NXT) is up 13% at $120.00 [3] - High Roller Technologies, Inc. (ROLR) is up 7% at $7.56 [3] Premarket Losers - Flora Growth Corp. (FLGC) is down 34% at $7.20 [4] - TEN Holdings, Inc. (XHLD) is down 29% at $2.47 [4] - Global Interactive Technologies, Inc. (GITS) is down 22% at $3.25 [4] - 5E Advanced Materials, Inc. (FEAM) is down 15% at $2.70 [4] - Vyome Holdings, Inc. (HIND) is down 14% at $2.79 [4] - Altimmune, Inc. (ALT) is down 11% at $5.48 [4] - BiomX Inc. (PHGE) is down 10% at $6.22 [4] - Qorvo, Inc. (QRVO) is down 9% at $74.94 [4] - Nuwellis, Inc. (NUWE) is down 9% at $3.45 [4] - Brenmiller Energy Ltd (BNRG) is down 9% at $2.90 [4]

分组1 - F5, Inc. reported better-than-expected first-quarter financial results, with earnings of $4.45 per share, surpassing the analyst consensus estimate of $3.65 by 21.88% [1] - The company's quarterly revenue reached $822.47 million, exceeding the Street estimate of $758.08 million [1] - F5 issued second-quarter sales guidance above estimates and raised its FY26 guidance above estimates [1] 分组2 - F5 shares rose 10.9% to $299.99 in pre-market trading following the positive financial results [2]

分组1 - U.S. stocks showed mixed performance, with the Dow Jones falling approximately 200 points on Friday [1] - Booz Allen Hamilton Holding Corporation reported fiscal Q3 earnings with adjusted EPS of $1.77, exceeding analyst expectations of $1.29 [1] - Quarterly sales for Booz Allen Hamilton were $2.62 billion, a decline of 10.2% year-on-year, which fell short of the expected $2.75 billion [1] - Following the earnings report, Booz Allen Hamilton shares increased by 9.8% to $105.09 [1] 分组2 - Life360 shares surged by 26.6% to $69.41 after raising FY25 sales guidance [3] - Sigma Lithium Corp experienced a gain of 16.7%, reaching $14.64 [3] - Avino Silver & Gold Mines Ltd rose by 15.2% to $9.02, with a price target increase from $5.5 to $7.25 by Roth Capital analyst Joe Reagor [3] - Clearpoint Neuro Inc shares increased by 14.6% to $16.28 [3] - Altimmune Inc gained 13% to $6.08 [3] - Redwire Corp rose by 12.4% to $13.44, following President Trump's announcement on the "Golden Dome" initiative [3] - JinkoSolar Holding Co., Ltd saw an 11.2% increase to $28.30 [3] - Telefonaktiebolaget LM Ericsson – ADR gained 9.5% to $10.49 after reporting better-than-expected quarterly results and proposing a higher dividend [3] - Hycroft Mining Holding Corporation increased by 9.3% to $51.05 [3] - Evolution Metals & Technologies Corp rose by 7.7% to $10.58 [3]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 500 points on Monday [1] Company Highlights - Altimmune Inc (NASDAQ:ALT) saw a significant increase of 23.6%, reaching $4.34, following the FDA's grant of Breakthrough Therapy Designation for Pemvidutide in MASH [1] - GH Research PLC (NASDAQ:GHRS) surged by 33.8% to $17.72 after the FDA lifted the clinical hold on its Investigational New Drug Application for GH001 [2] - Vicor Corp (NASDAQ:VICR) rose by 20.7% to $141.08 [2] - Critical Metals Corp (NASDAQ:CRML) increased by 19.6% to $9.71 [2] - Kosmos Energy Ltd (NYSE:KOS) gained 19.3% to $1.06 after issuing an operational and financial update [2] - TRON Inc (NASDAQ:TRON) increased by 16.9% to $1.59 [2] - Nuscale Power Corp (NYSE:SMR) rose by 15.7% to $18.88 [2] - Regencell Bioscience Holdings Ltd (NASDAQ:RGC) increased by 15.4% to $23.71 [2] - Rayonier Advanced Materials Inc (NYSE:RYAM) gained 14.1% to $6.68, with the appointment of Scott M. Sutton as President and CEO [2] - Aduro Clean Technologies Inc (NASDAQ:ADUR) rose by 14% to $12.05 [2] - Gyre Therapeutics Inc (NASDAQ:GYRE) increased by 12.7% to $7.67, announcing alignment with China's CDE on conditional approval pathway for hydronidone [2] - Endeavour Silver Corp (NYSE:EXK) gained 12.5% to $10.16 [2] - Allegro MicroSystems Inc (NASDAQ:ALGM) surged by 11.9% to $30.12 [2] - United States Antimony Corp (NYSE:UAMY) rose by 11.7% to $6.69 [2] - Oklo Inc (NYSE:OKLO) gained 11.5% to $86.82 [2] - Figure Technology Solutions Inc (NASDAQ:FIGR) increased by 11.3% to $48.66 [2] - Valero Energy Corp (NYSE:VLO) rose by 9.6% to $181.21 [2] - AeroVironment, Inc. (NASDAQ:AVAV) increased by 8.6% to $278.31 [2] - Coeur Mining Inc (NYSE:CDE) gained 8.5% to $19.05 [2] - Halliburton Co (NYSE:HAL) rose by 7.8% to $31.92, with U.S. energy stocks trading higher amid news of potential investments in Venezuela's oil industry [2] - Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) gained 7.7% to $85.39 [2] - Slb NV (NYSE:SLB) increased by 7.4% to $43.19 [2] - Amkor Technology Inc (NASDAQ:AMKR) rose by 7.3% to $46.05, with Needham analyst Charles Shi maintaining a Buy rating and raising the price target from $37 to $50 [2]

Group 1 - Citizens JMP analyst Jonathan Wolleben lowered the price target on Altimmune (ALT) to $14 from $15 while maintaining an Outperform rating on the shares [1] - The firm anticipates the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting, with 48-week data expected to be released this quarter [1]